With the increasingly large proportion of elderly individuals in our populations, the hip fracture incidence curve is shifting to the right and hip fracture patients are becoming a more heterogeneous group ([@CIT0002]). Almost all excess mortality occurs within the first 3 months after surgery ([@CIT0015]). A large meta-analysis has found a 5- to 8-fold increased risk of mortality during this period ([@CIT0007]). Several factors that may be predictive of death have been identified ([@CIT0015]). We studied the predictive value (for mortality) of routine blood tests.

Patients and methods {#ss2}
====================

792 hip fracture patients aged 60 or older who were admitted to the Department of Orthopedics, Bispebjerg University Hospital, Denmark from October 2008 through July 2010 were included prospectively. 67 patients aged less than 60 were excluded. Follow-up data on mortality were obtained from the civil registration system on August 1, 2010. Patients were included in the study within the first 3 days after admission.

Because of various logistical problems, not all blood tests were done for some patients in the study ([Table 1](#T1){ref-type="table"}). The patients were divided into 2 groups based on whether they survived for at least 90 days after the hip fracture.

###### 

Characteristics of the cohort and blood sample values at the time of admission

                                                                      Hip fracture patients                                  
  ------------------------------------------------------------------- ----------------------- -------------- --------------- ----------
  Number                                                              792                     560            232             
  Age, mean (SD)                                                                                                             
   Women                                                              591                     83 (9)         87 (8)          \< 0.001
   Men                                                                201                     78 (9)         83 (9)          \< 0.001
  Sex, n (%)                                                                                                                 
   Women                                                              591                     425 (76%)      166 (72%)       
   Men                                                                201                     135 (24%)      66 (28%)        0.2
  Blood hemoglobin (mmol/L), mean (SD).                                                                                      
  Reference interval: women: 7.3--9.5 mmol/L, men: 8.5--10.3 mmol/L                                                          
   Women                                                              590                     7.5 (1.1)      7.3 (1.0)       0.02
   Men                                                                201                     8.0 (1.2)      7.2 (1.2)       \< 0.001
  Plasma creatinine (μmol/L), median (range).                                                                                
  Ref. int.: women: 50--90 μmol/L, men: 60--105 μmol/L                                                                       
   Women                                                              585                     68 (33--445)   82 (36--615)    \< 0.001
   Men                                                                200                     82 (39--419)   106 (50--699)   \< 0.001
  Plasma sodium (mmol/L), mean (SD).                                                                                         
  Ref. int.: 137--144 mmol/L                                                                                                 
   Women                                                              587                     137 (4.1)      137 (5.1)       0.4
   Men                                                                201                     138 (4.3)      138 (4.6)       0.5
  Plasma potassium (mmol/L), mean (SD).                                                                                      
  Ref. int.: 3.5--4.6 mmol/L                                                                                                 
   Women                                                              587                     3.8 (0.49)     4.0 (0.67)      0.002
   Men                                                                201                     4.0 (0.49)     4.1 (0.59)      0.2
  Plasma glucose (mmol/L), mean (SD).                                                                                        
  Ref. int.: 4.2--7.2 mmol/L                                                                                                 
   Women                                                              556                     6.8 (2.1)      6.5 (1.7)       0.1
   Men                                                                185                     6.6 (2.3)      6.8 (2.1)       0.5
  Plasma albumin (g/L), mean (SD).                                                                                           
  Ref. int.: 34--45 g/L                                                                                                      
   Women                                                              515                     39 (4.4)       37 (5.4)        \< 0.001
   Men                                                                174                     39 (4.7)       36 (5.6)        0.003
  Plasma CRP (mg/L), median (range).                                                                                         
  Ref. int.: \< 10 mg/L                                                                                                      
   Women                                                              458                     67 (82)        71 (73)         0.05
   Men                                                                170                     66 (70)        81 (86)         0.2
  Leukocyte count (× 10^9^/L), mean (SD).                                                                                    
  Ref. int.: 3.5--8.8 × 10^9^/L                                                                                              
   Women                                                              590                     11.0 (4.0)     10.8 (4.1)      0.7
   Men                                                                201                     11.5 (5.6)     10.5 (4.3)      0.1
  Platelet count (× 10^9^/L), mean (SD).                                                                                     
  Ref. int.: 145--390 × 10^9^/L                                                                                              
   Women                                                              590                     249 (86)       270 (80)        0.007
   Men                                                                201                     229 (79)       240 (90)        0.4

Blood was analyzed for hematology and chemistry using Sysmex (Sysmex Corporation, Kobe City, Japan) and Vitros 5.1 FS (Ortho-Clinical Diagnostics, Pisataway, NJ) respectively, using standardized routine laboratory methods.

The study was approved by the local ethics committee and by the Danish data protection agency, and it was carried out in line with the Helsinki Declaration.

Statistics {#ss3}
----------

Continuous variables are presented as mean (SD) or median (range). We used student\'s t-test for continuous, normally distributed variables, Mann-Whitney 2-sample statistics for skewed distributions, and Chi-squared test to compare categorical variables. To estimate which laboratory tests could be used to predict outcome, we used receiver operation characteristic (ROC) curves and calculated the area under the curve (AUC) for the different tests. Cutoff values for the different laboratory tests were predicted using ROC curves or based on the test performance in a normal cohort. Univariate and multivariate logistic regression analyses were used to examine the relationship between the various risk factors and outcome. Values of p \< 0.05 were considered statistically significant. Data were analyzed using STATA software.

Results {#ss4}
=======

232 of 792 patients (29%) died during the study period ([Table 1](#T1){ref-type="table"}), at median 44 (1--582) days. 57 died between 1 and 66 days, while still in hospital. 106 died after leaving hospital but within 3 months, and 69 died some time after 3 months. Based on the ROC curves ([Figure 1](#F1){ref-type="fig"}), the cutoff values were set at 7 mmol/L in both sexes for hemoglobin and above 50 mg/L for C-reactive protein (CRP). The ROC curves for most other laboratory tests did not indicate any optimal cutoff value (the number of correctly classified patients was the same for a large variety of values) ([Table 2](#T2){ref-type="table"}). We therefore decided to use the upper or lower limits of normal laboratory reference intervals as cutoff values.

![ROC curves for prediction of mortality in relation to laboratory values at admission. The curves represent plasma creatinine (crea, solid line), inverse blood hemoglobin (hb, dashed line), and plasma potassium (K, dotted line). Hemoglobin values were converted because the association with death followed decreasing values.](ORT-0300-9734-083-031_g001){#F1}

###### 

Area under the curve (AUC) for the routine laboratory tests included in the study

                          Area under ROC **[^a^](#T2-N1){ref-type="fn"}**   SE **[^b^](#T2-N2){ref-type="fn"}**   95% CI
  ----------------------- ------------------------------------------------- ------------------------------------- ------------
  Plasma creatinine       0.69                                              0.02                                  0.64--0.74
  Plasma potassium        0.61                                              0.02                                  0.55--0.66
  Blood hemoglobin        0.60                                              0.02                                  0.55--0.65
  Plasma albumin          0.59                                              0.02                                  0.53--0.64
  Blood platelet count    0.58                                              0.02                                  0.53--0.63
  Plasma CRP              0.55                                              0.02                                  0.50--0.60
  Blood glucose           0.52                                              0.02                                  0.47--0.57
  Blood leukocyte count   0.52                                              0.02                                  0.47--0.57
  Plasma sodium           0.51                                              0.02                                  0.46--0.56

**^a^** Receiver operating curve

**^b^** standard error

In the univariate analysis ([Table 3](#T3){ref-type="table"}), high age, high plasma creatinine ([Figure 2](#F2){ref-type="fig"}), low plasma albumin, high plasma potassium, and low blood hemoglobin led to increased mortality. Patient mortality was not related to gender, blood platelet count, or CRP. After adjustment in the multivariate logistic regression model, age, plasma creatinine, plasma potassium, plasma albumin remained as risk factors.

###### 

Unadjusted and adjusted risk factors influencing mortality after hip fracture

  Risk factors                                                         Died   Survivors   Unadjusted OR       p-value    Adjusted OR         p-value
  -------------------------------------------------------------------- ------ ----------- ------------------- ---------- ------------------- ----------
  Sex (male)                                                           29     24          1.26 (0.85--1.85)   0.3        1.33 (0.86--2.06)   0.2
  Age \> 80 years                                                      85     64          3.21 (2.03--5.09)   \< 0.001   2.92 (1.78--4.81)   \< 0.001
  Creatinine (\> 90 and \>105 μmol/L in women and men, respectively)   52     21          4.19 (2.91--6.03)   \< 0.001   2.84 (1.90--4.25)   \< 0.001
  Potassium (\> 4.5 mmol/L)                                            22     4           6.10 (3.59--10.4)   \< 0.001   3.64 (2.01--6.61)   \< 0.001
  Hemoglobin(\< 7 mmol/L)                                              40     25          1.92 (1.34--2.77)   \< 0.001   1.13 (0.75--1.71)   0.6
  Albumin (\< 34 g/L)                                                  8      3           3.04 (1.48--6.27)   0.002      3.08 (1.33--7.15)   0.009
  Platelet count (\> 390 × 10^9^/L)                                    9      5           1.78 (0.95--3.32)   0.07       1.43 (0.69--2.94)   0.3
  CRP (\> 50 mg/L)                                                     59     56          1.16 (0.82--1.65)   0.4        1.11 (0.75--1.62)   0.6

![Kaplan Meier plot: mortality in relation to creatinine levels at admission. 3-month mortality after hip fracture. The plot on the left is divided into groups with elevated plasma creatinine (dotted line) and normal plasma creatinine (solid line). Plasma creatinine was elevated if above 105 μmol/L in males and 90 μmol/L in females. The plot on the right is divided into quartiles of plasma creatinine.](ORT-0300-9734-083-031_g002){#F2}

Discussion {#ss5}
==========

Previous studies on mortality after hip fracture have found an association with plasma creatinine levels ([@CIT0012], [@CIT0018], [@CIT0004], [@CIT0001], [@CIT0009]), which is what we found in the present study. Of these previous studies, the most comprehensive was a prospective observational study of 2,963 consecutive patients by [@CIT0012]. They found that serum urea was an independent predictor of mortality at 30 and 90 days, and also at 1 and 2 years. Furthermore, mortality was also higher in patients admitted with raised or low serum sodium, raised serum potassium, and raised serum creatinine. A prospective cohort study of 436 patients in Sweden found that in bivariate analysis, a creatinine concentration of more than 100 umol/L on admission was a risk factor for poor 4-month survival. Using multiple logistic regression analysis, creatinine was not found to be an independent risk factor ([@CIT0004]).

In both of the above-mentioned studies, the cutoff value for elevated creatinine was set differently than in our study, and it appears that the same value was used for both sexes. In our study, the cutoff level for elevated serum creatinine was set at 105 μmol/L for men and 90 μmol/L for women, as these are the upper limits of 95% CI in normal Scandinavian subjects ([@CIT0005]).

A recent Norwegian study on 364 hip fracture patients found that the use of diuretics, followed by the presence of congestive heart disease on admission, were the strongest predictors of 1-year mortality ([@CIT0010]). These findings suggest that the increased mortality in patients with elevated creatinine may be due to congestive heart disease that is severe or poorly regulated. The added strain of hospitalization and surgery may lead to the increased mortality. Concerning serum albumin, several previous studies have found it to be associated with mortality after hip fractures ([@CIT0011], [@CIT0017], [@CIT0013], [@CIT0016], [@CIT0014]).

A recent retrospective study of 200 patients ([@CIT0013]) suggested that serum albumin at admission and total lymphocyte count could serve as markers of malnutrition and could be used to predict clinical outcome after hip fractures. However, only levels of albumin at admission and age were found to be independent prognostic factors for 1-year mortality by Cox regression analysis, with hazard ratios of 0.93 (95% CI: 0.89--0.98; p = 0.007) and 1.04 (95% CI: 1.007--1.07; p = 0.02) respectively. In the same study, patients with low albumin at admission had an odds ratio of 4.0 (95% CI: 1.3--12.2; p = 0.02) for dying within 3 months of the fracture (as compared to patients with normal albumin levels). In a similar study ([@CIT0011]), patients were regarded as being malnourished based on total lymphocyte count and albumin levels at admission. Patients with reduced values for both parameters on admission were 3.5 times more likely to die within 1 year of surgery (p \< 0.01).

A recent study from Canada of 583 hip fracture patients found an association between low serum albumin levels at admission and in-hospital mortality (Pimlott et al. 2010). After multivariate adjustment, an association between low serum albumin and mortality was found to be statistically significant with an adjusted OR of 2.4 (95% CI: 1.2--5.1; p \< 0.05). Almost half of the hip fracture patients had low serum albumin at the time of admission and it was independently associated with 2.5-fold greater odds of short-term mortality.

The association between mortality after hip fracture and reduced hemoglobin levels at admission has also been reported in previous studies ([@CIT0006], [@CIT0008], [@CIT0003]). In a American study of 548 hip fracture patients ([@CIT0008]), 60-day mortality after hip fracture was associated with admission levels of hemoglobin, giving an adjusted odds ratio of 0.69 (95% CI: 0.49--0.95; p \< 0.05). The authors theorized that the degree of anemia is a marker of underlying comorbid illness burden and physiological reserve. A study on 395 patients found that patients with anemia on admission were more likely to die within 6 or 12 months of hip fracture surgery ([@CIT0006]). The severity of anemia was associated with an increased risk of mortality. In the same study, anemia on admission was not predictive of 3-month mortality, but was predictive of mortality at 6 and 12 months after hip fracture.

The strength of our study is that the mortality data has been validated. However, we have no information on the cause of death. It is uncertain whether preoperative correction of elevated serum creatinine levels would be beneficiary, but we are currently planning studies to investigate this.
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